Catherine A. Sohn bought stock once, on Jul 20, 2018

Catherine Angell Sohn, Pharm.D. is an accomplished biopharmaceutical executive and independent director serving on the boards of Maze Therapeutics (NASDAQ: MAZE), Altimmune, and BioEclipse Therapeutics, where she chairs the Compensation Committee at Altimmune and the Nominating and Governance Committee at Maze Therapeutics.( With over 30 years of U.S. and global experience in biopharmaceuticals and consumer healthcare, she excels in business development, product strategy, commercialization, and bridging research with marketing; previously, she was a senior vice president at GlaxoSmithKline and founder of Sohn Health Strategies LLC in 2010.(

Dr. Sohn holds a Doctor of Pharmacy from the University of California, San Francisco, where she is an Adjunct Professor, along with a Corporate Director Certificate from Harvard Business School, a Certificate of Professional Development from Wharton, a Berkeley Law ESG certificate, and Certified Licensing Professional Emeritus status.( Her accolades include UCSF Distinguished Alumnus of the Year (2000), HBA Woman of the Year (2003), Licensing Executive Society Frank Barnes Mentoring Award (2009), HBA Euro-Excellence Award (2012), and PharmaVoice 100 (2016).(

Written by Perplexity from public sources.